I'm LongbridgeAI, I can summarize articles.Bio Essence reported a significant revenue increase to $1.898 million in 2025, up from $0.324 million in 2024, driven by a strategic shift to outsourced OEM manufacturing services. The company achieved a net income of $896,197 and earnings per share of $0.02, marking a return to profitability. Key highlights include a 486% revenue growth, improved gross profit of $1.428 million, and a controlled cost structure. The company has ceased in-house product sales and now focuses solely on OEM services following the sale of its previous subsidiaries.
Bio Essence reported a sharp revenue rebound to $1.898 million in 2025, driven by increased OEM service volume, with basic and diluted net income per share of $0.02 reflecting a return to profitability. The improvement in top-line sales and higher gross margins on OEM services contributed to operating income of $900,011 and net income of $896,197 for the year. These results follow a strategic shift away from in‑house product sales toward outsourced OEM manufacturing services.
Financial Highlights
- Total revenues: $1.898 million (up from $0.324 million in 2024)
- Gross profit: $1.428 million (up from $0.217 million in 2024)
- Income (loss) from operations: $900,011 (compared to $(459,438) in 2024)
- Net income (loss): $896,197 (compared to $(1,308,796) in 2024)
- Basic and diluted net income per share: $0.02 (compared to $(0.03) per share in 2024)
Business Highlights
- Revenue growth driver: Revenue surged approximately 486% to $1.90M in 2025, primarily from large OEM service orders from three new major clients.
- Channel shift: The company executed a strategic pivot from product sales to providing OEM manufacturing services; product sales declined to nil in 2025.
- Operational outsourcing: Following the sale of BEP and BEH, the company now outsources manufacturing and OEM operations rather than conducting in‑house production.
- Cost and margin momentum: As OEM services scaled, gross profit improved materially while the company maintained a controlled cost structure.
- R&D subsidiary status: McBE, an R&D/prescription drug focused subsidiary, was formed and later dissolved; the company remains concentrated on supplement OEM services.
Original SEC Filing: Bio Essence Corp [ BIOE ] - 10-K - Mar. 27, 2026